Welcome to our dedicated page for Heron Therapeutics news (Ticker: HRTX), a resource for investors and traders seeking the latest updates and insights on Heron Therapeutics stock.
Heron Therapeutics, Inc. (Nasdaq: HRTX) is a commercial-stage biotechnology company whose news flow is closely tied to its acute care and oncology supportive care portfolio. The company regularly issues updates on its marketed products ZYNRELEF, APONVIE, CINVANTI, and SUSTOL, as well as financial and corporate developments that affect HRTX stock.
On this page, readers can follow HRTX news related to quarterly and annual financial results, net revenue trends by product, and guidance updates disclosed in earnings press releases. Heron’s announcements often break out performance for its Acute Care franchise, which includes ZYNRELEF for postoperative pain and APONVIE for prevention of postoperative nausea and vomiting in adults, and its Oncology franchise, which includes CINVANTI and SUSTOL for prevention of chemotherapy-induced nausea and vomiting.
Company news also covers regulatory and clinical milestones for Heron’s products. Examples from past releases include FDA approvals and label expansions for ZYNRELEF in various soft tissue and orthopedic surgical procedures, and recognition of APONVIE in consensus guidelines for the management of postoperative nausea and vomiting. These items help investors and clinicians track how product indications and clinical positioning evolve over time.
In addition, Heron reports capital markets and governance events through press releases and corresponding SEC filings. Recent topics have included comprehensive capital restructuring, new credit facilities and convertible note transactions, adoption of a Tax Benefit Preservation Plan to protect net operating loss carryforwards, and Board-level changes such as cooperation agreements with investors and director appointments. For users monitoring HRTX, this news feed offers a consolidated view of operational, financial, regulatory, and governance developments that the company has publicly disclosed.
Heron Therapeutics, Inc. (Nasdaq: HRTX) will host a conference call and webcast on November 8, 2022, at 4:30 p.m. ET, to discuss its third quarter 2022 financial results and recent business highlights. Investors can join the call by dialing (646) 307-1963 for domestic calls or (800) 715-9871 for international calls, using the passcode 4433557. The event will also be available via webcast on Heron's website, with an archived version accessible for 60 days post-event.
Heron Therapeutics has received FDA approval for APONVIE (aprepitant), the first intravenous formulation for preventing postoperative nausea and vomiting (PONV) in adults. Administered as a single 30-second IV injection, APONVIE achieves therapeutic levels rapidly and maintains them for at least 48 hours. Clinical studies showed APONVIE was more effective than standard treatments, reducing vomiting in patients post-surgery. This launch expands Heron's acute care portfolio, targeting approximately 36 million surgical procedures annually in the U.S.
Heron Therapeutics, Inc. (Nasdaq: HRTX) announced a private placement to raise approximately $76.5 million by selling 16,129,032 shares of common stock at $3.10 per share. This funding, led by Deep Track Capital, LP, aims to support the company's acute care and oncology franchises, including the anticipated launch of HTX-019 for postoperative nausea and vomiting. The placement is expected to close on August 11, 2022. The company also plans to file a registration statement with the SEC for the resale of these shares.
Heron Therapeutics reported significant growth in the second quarter of 2022, with ZYNRELEF product sales soaring by 140% sequentially, reaching $2.5 million. The oncology care franchise saw net sales climb 12% to $25.1 million, prompting an increase in full-year sales guidance to $93 million to $95 million. The company anticipates over $50 million in cost reductions due to restructuring efforts. Pro-forma cash post-private placement stands at $158.7 million, ensuring a cash runway through 2024.
Heron Therapeutics (HRTX) will host a conference call on August 9, 2022, at 8:30 a.m. ET to discuss its second quarter 2022 financial results and recent business developments. The call is accessible via phone or webcast, with an archive available for 60 days post-call. Heron focuses on developing therapeutic innovations to enhance medical care, particularly for acute care and oncology patients. Interested parties can find more details on the company's website.
Summary not available.
Heron Therapeutics, Inc. (HRTX) announced a study published in the Journal of Knee Surgery evaluating the safety and efficacy of ZYNRELEF as part of a non-opioid multimodal analgesic regimen for total knee arthroplasty (TKA). The study found over 80% of patients did not experience severe pain post-surgery, with 12% remaining opioid-free. ZYNRELEF demonstrated improved pain control compared to standard treatments, showing no safety concerns. The company emphasizes the need for controlled trials to confirm these promising results and maintain ZYNRELEF's potential in outpatient settings.
Heron Therapeutics, Inc. (Nasdaq: HRTX) announced its participation in the 2022 Jefferies Global Healthcare Conference on June 8, 2022, at 8:30 am ET. The event runs from June 8-10 in New York, NY. A live webcast will be available on their website under the Investor Resources section. Heron focuses on developing therapeutic innovations to enhance medical care for patients, particularly in acute care and oncology.
Heron Therapeutics (HRTX) presented interim data from a Phase 2 study of ZYNRELEF at the SOAP 54th Annual Meeting. ZYNRELEF, approved for postoperative analgesia, showed low levels of bupivacaine and meloxicam in breast milk post-administration in women undergoing C-sections. Results indicated ZYNRELEF was well-tolerated and effectively reduced postoperative opioid use, with 27% of patients experiencing opioid-free recovery. The findings suggest ZYNRELEF could significantly enhance pain management for postpartum women while minimizing opioid exposure.
Heron Therapeutics (HRTX) reported Q1 2022 net product sales of $23.5 million, marking a year-over-year increase from $20 million. ZYNRELEF unit demand rose by 68%, supported by CMS's approval of a 3-year transitional pass-through status starting April 1, enabling separate reimbursements outside surgical bundle payments. Additionally, the company's oncology care franchise generated $22.4 million in net revenue, a 13% rise over the prior quarter, with full-year guidance set between $89 million and $93 million. However, net loss increased to $63.9 million, or $0.63 per share.